Recent Updates
Recently added Catalysts

EGFR Mutation-positive Non-Small Cell Lung Cancer: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.4Buniverse median $1.20B
Allocated capital$289M$1.4B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank240/299crowding rank 243

EGFR Mutation-positive Non-Small Cell Lung Cancer is uncontested. ArriVent BioPharma (AVBP) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Pemetrexed Disodium in phase 3.

There is no public comparable to price it against. AVBP spreads its $1.4B market cap across 5 indications, so $289M of it is allocated here.

The one programme here is in late-stage development, but it carries no dated catalyst in the next 12 months.

$289M of allocated capital sits in EGFR Mutation-positive Non-Small Cell Lung Cancer, ranking it 240th of 299 indications by the money committed to it.

Companies developing drugs for EGFR Mutation-positive Non-Small Cell Lung Cancer 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
AVBPArriVent BioPharmaPemetrexed DisodiumPhase 32$1.4BNo5No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why EGFR Mutation-positive Non-Small Cell Lung Cancer counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. EGFR Mutation-positive Non-Small Cell Lung Cancer has one competitor and a median of $1.4B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Metastatic Non-Small Cell Lung Cancer1 company · $289M · median $1.4BUncontestedAdvanced Colorectal Carcinoma1 company · $289M · median $1.4BUncontestedHigh-Grade Glioma1 company · $299M · median $897MUncontestedLow and Intermediate-1 Risk Myelodysplastic Syndrome1 company · $299M · median $897MUncontestedMerkel Cell Carcinoma1 company · $321M · median $1.3BUncontestedRecurrent Acute Myeloid Leukemia1 company · $243M · median $970MUncontestedAdvanced Multiple Myeloma1 company · $230M · median $460MUncontestedRefractory/ Relapsed Non-Hodgkin Lymphoma1 company · $203M · median $610MUncontested

EGFR Mutation-positive Non-Small Cell Lung Cancer pipeline questions

Which biotech companies are developing drugs for EGFR Mutation-positive Non-Small Cell Lung Cancer?

ArriVent BioPharma (AVBP, Pemetrexed Disodium, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in EGFR Mutation-positive Non-Small Cell Lung Cancer.

How advanced is the EGFR Mutation-positive Non-Small Cell Lung Cancer pipeline?

Of the 1 clinical-stage programme in EGFR Mutation-positive Non-Small Cell Lung Cancer, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for EGFR Mutation-positive Non-Small Cell Lung Cancer?

No. AVBP is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in EGFR Mutation-positive Non-Small Cell Lung Cancer, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map